News
LCTX
0.9379
+1.13%
0.0105
Weekly Report: what happened at LCTX last week (0928-1002)?
Weekly Report · 1d ago
Weekly Report: what happened at LCTX last week (0921-0925)?
Weekly Report · 09/28 09:40
Analysts Are Bullish on These Healthcare Stocks: Lineage Therap (LCTX), Lyell Immunopharma (LYEL)
TipRanks · 09/25 08:30
Weekly Report: what happened at LCTX last week (0914-0918)?
Weekly Report · 09/21 09:40
Weekly Report: what happened at LCTX last week (0907-0911)?
Weekly Report · 09/14 09:42
Lineage Cell announces issuance of patent underlying AlloSCOPE 5D platform
TipRanks · 09/08 12:15
Weekly Report: what happened at LCTX last week (0831-0904)?
Weekly Report · 09/07 09:39
Lineage Cell Therapeutics: Balancing An Out-Licensed Pipeline Against Clinical Risk
Seeking Alpha · 09/01 21:50
Weekly Report: what happened at LCTX last week (0824-0828)?
Weekly Report · 08/31 09:43
Lineage Cell Therapeutics management to meet with B. Riley
TipRanks · 08/24 16:50
Weekly Report: what happened at LCTX last week (0817-0821)?
Weekly Report · 08/24 09:43
Weekly Report: what happened at LCTX last week (0810-0814)?
Weekly Report · 08/17 09:44
Lineage Maintained at Buy with Unchanged $3 Target as Cell Therapy Pipeline and DOSED SCI Trial Advance
TipRanks · 08/12 19:05
Weekly Report: what happened at LCTX last week (0803-0807)?
Weekly Report · 08/10 09:41
Lineage Cell Therapeutics Balances Progress and Risk
TipRanks · 08/08 00:13
Lineage Maintained at Buy as Analyst Cites Clinical Momentum and Strategic Backing; $9 Price Target Reaffirmed
TipRanks · 08/07 20:26
Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Lineage Therap (LCTX) and BioLife Solutions (BLFS)
TipRanks · 08/07 15:00
Lineage Cell Therapeutics GAAP EPS of -$0.03 in-line, revenue of $1.07M misses by $0.46M
Seeking Alpha · 08/06 20:54
Lineage Cell Therapeutics reports Q2 EPS (3c), consensus (3c)
TipRanks · 08/06 20:17
*Lineage Cell Therapeutics: Runway Expected to Support Planned Ops Into 3Q 2028 >LCTX
Dow Jones · 08/06 20:02
More
Webull provides a variety of real-time LCTX stock news. You can receive the latest news about Lineage Cell The through multiple platforms. This information may help you make smarter investment decisions.
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).